ORMP - NASDAQ

Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc.

ORMPยทNASDAQ

$3.65

-1.6%
HealthcareBiotechnology

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$149.38M
EPS1.5300
P/E Ratio2.39
Earnings Date06/03/2026
Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc. Fair Value Envelope

ORMP ยท NASDAQ

Our analysis suggests that ORMP has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.65, this represents a potential HIDDEN relative to our calculated worth for Oramed Pharmaceuticals Inc..

HIDDEN
Intrinsic Value
Current Price: $3.65

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$16.4M
+ Cash & Equivalents$45.9M
Firm Value$29.5M
- Debt$825.0K
Equity Value$28.7M
/ Shares Outstanding40,816,326B
DCF Value$1
OVERVALUED BY 81%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$6.3M
-$4.3M
-$3.0M
-$2.0M
-$1.4M
-$952.1K
-$653.0K
-$447.9K
-$307.2K
-$210.7K
Maintenance CapEx
-$265.2K
-$181.9K
-$124.7K
-$85.6K
-$58.7K
-$40.2K
-$27.6K
-$18.9K
-$13.0K
-$8.9K
Owner Earnings
-$6.5M
-$4.5M
-$3.1M
-$2.1M
-$1.4M
-$992.4K
-$680.6K
-$466.8K
-$320.2K
-$219.6K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$6.1M
-$3.8M
-$2.4M
-$1.6M
-$984.7K
-$625.4K
-$397.1K
-$252.2K
-$160.2K
-$101.7K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your ORMP research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.